Compugen (CGEN)vsRegeneron Pharmaceuticals Inc (REGN)
CGEN
Compugen
$2.47
+0.41%
HEALTHCARE · Cap: $233.97M
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 20893% more annual revenue ($15.53B vs $74.00M). CGEN leads profitability with a 47.6% profit margin vs 27.9%. CGEN appears more attractively valued with a PEG of 1.29. REGN earns a higher WallStSmart Score of 66/100 (B-).
CGEN
Buy60
out of 100
Grade: C+
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGEN.
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Keeps 48 of every $100 in revenue as profit
Revenue surging 107.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Operating margin of -339.6%
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 47.6% and operating margin at -339.6%. Revenue growth of 107.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap, Altman Z-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
CGEN carries more volatility with a beta of 2.79 — expect wider price swings.
CGEN is growing revenue faster at 107.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (66/100 vs 60/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?